Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NEK2 | P51955 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL412887 | 0.89 | NEK2 (0.52) | PDGFRBMAPTERN1LMNATP53 | |
| SCHEMBL10189713 | 0.87 | MAPT (0.42) | MAPTERN1LMNAMAP2K4MAPK1 | |
| SCHEMBL411645 | 0.86 | MAPT (0.44) | PDGFRBMAPTLMNATP53CDK4 | |
| SCHEMBL14847310 | 0.85 | TPMT (0.52) | PDGFRBMAPTERN1LMNATP53 | |
| SCHEMBL13041108 | 0.83 | KDR (0.52) | PDGFRBMAPTCDK4CCNA2CCND1 | |
| SCHEMBL411640 | 0.82 | KDM4E (0.44) | CDK4CCNA2CCND1CDK2CCND3 | |
| SCHEMBL411698 | 0.82 | TUBB4A (0.56) | PDGFRBMAPTLMNATP53MAPK1 | |
| SCHEMBL409160 | 0.81 | TUBB1 (0.46) | CDK4CCNA2CCND1CDK2CCND3 | |
| SCHEMBL410428 | 0.81 | FYN (0.48) | CDK4CCNA2CCND1CDK2CCND3 | |
| SCHEMBL411388 | 0.81 | TUBB4A (0.54) | PDGFRBMAPTLMNATP53MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9175022-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9175022-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130338112-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2013-12-19 | — | — | US | disclosed |
| US-8501790-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501790-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-1919881-B1 | 1, 2, 3 -TRIAZOLES INHIBITORS OF TUBULIN POLYMERIZATION FOR THE TREATMENT OF POLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2013-04-10 | — | — | EP | disclosed |
| EP-1919881-B1 | 1, 2, 3 -TRIAZOLES INHIBITORS OF TUBULIN POLYMERIZATION FOR THE TREATMENT OF POLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20120022118-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-01-26 | — | — | US | disclosed |
| US-20120022118-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-01-26 | — | — | US | disclosed |
| US-20100279410-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2010-11-04 | — | — | US | disclosed |
| US-7781462-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20100093670-A1 | Compounds for the treatment of angiogenesis | SYNTA PHARMACEUTICALS CORP. | 2010-04-15 | — | — | US | disclosed |
| EP-2059250-A2 | COMPOUNDS FOR THE TREATMENT OF ANGIOGENESIS | Synta Pharmaceuticals Corporation (US) | 2009-05-20 | — | — | EP | disclosed |
| EP-1919881-A1 | 1, 2, 3 -TRIAZOLES INHIBITORS OF TUBULIN POLYMERIZATION FOR THE TREATMENT OF POLIFERATIVE DISORDERS | Synta Pharmaceuticals Corporation (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008033449-A2 | COMPOUNDS FOR THE TREATMENT OF ANGIOGENESIS | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20070238699-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-10-11 | — | — | US | disclosed |
| US-20070238699-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-10-11 | — | — | US | disclosed |
| US-20070238699-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-10-11 | — | — | US | disclosed |
| WO-2007014198-A1 | 1, 2, 3 -TRIAZOLES INHIBITORS OF TUBULIN POLYMERIZATION FOR THE TREATMENT OF POLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007014198-A1 | 1, 2, 3 -TRIAZOLES INHIBITORS OF TUBULIN POLYMERIZATION FOR THE TREATMENT OF POLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238699-A1 | Compounds for the treatment of proliferative disorders | RB1, MKI67, MAPRE1 | PDGFRB 186/4885MAPT 95/4885ERN1 3240/4885 |
| US-20120022118-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | PDGFRB 186/4885MAPT 95/4885ERN1 3240/4885 |
| US-20100093670-A1 | Compounds for the treatment of angiogenesis | FLT4, FLT1, TEK | PDGFRB 46/4885MAPT 4120/4885ERN1 4136/4885 |
| US-20130338112-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | PDGFRB 186/4885MAPT 95/4885ERN1 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.